How Much Dantrolene? A Case of Fulminant Malignant Hyperthermia

Denborough M.A. Malignant hyperpyrexia. In: Clinics in Anaesthesiology 1984; 2, 3: 669–675.

Ward A. , Chaffman M.O. , Sorkin E.M. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the Neuroleptic Malignant Syndrome and an update of its use in muscle spasticity. Drugs 1986; 32: 130–168.

Heffron J.J.A. Malignant hyperthermia: Biochemical aspects of the acute episode. Br J Anaesth 1988; 60: 274–278.

Rosenberg H. Clinical presentation of malignant. hyperthermia. Br J Anaesth 1988; 60: 268–273.

Brandom B.W. , Cook D.R. Muscle relaxants in children. In: Seminars in Anesthesia 1985; IV, 1: 41–51.

Schwartz L. , Rockoff M.A. , Koka B.V. Masseter spasm: Incidence and implications. Anesthesiology 1984; 61: 772–775.

Ellis F.R. , Halsall P.J. Suxamethonium spasm. Br J Anaesth 1984; 56: 381–383.

Sessler D.I. Malignant hyperthermia. J Paediatr 1986; 109: 9–14.

Kolb M.E. , Horne M.L. , Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982; 56: 254–262.

Flewellen E.H. , Nelson T.E. , Jones W.P. , Arens J.F. , Wagner D.L. Dantrolene dose response in awake man: Implications for management of malignant hyperthermia. Anesthesiology 1983; 59: 275–280.

Britt B.A. Dantrolene-an update. In: Britt BA, ed, Malignant Hyperthermia. Martinus Nijhoff Publishing, Boston 1987; 325–368.

Australian Society of Anaesthetists. Newsletter, December 2, 1981.